Surrozen, Inc. provided third quarter 2023 financial results and business updates. Phase 1a data from SZN-043 and SZN-1326 primes Company to deliver key 2024 milestones focused on proof-of-concept data. SZN-043 is the first development candidate using Surrozen's SWEETS??

technology. Surrozen is developing SZN-043 for severe liver diseases, initially focusing on severe alcoholic hepatitis. The Company is enrolling patients in a Phase 1a clinical trials in patients with chronic liver disease and healthy volunteers, and the Company expects to announce data in first quarter 2024.

SZN-1326, SZN-043, and SZN-413 (including anticipated clinical development timelines and the availability of data, the potential and timeline to nominate the lead development candidate pursuant to its partnership with Boehringer Ingelheim and its expectations with respect to its cash runway. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical or clinical trials with respect to SZN-1326 and potential future drug candidates; the Company's ability to initiate a Phase 1b clinical study in patients with ulcerative colitis in 2024 and anticipate proof-of-concept data may be available in the second half of 2024. SZN-413 is a bi-specific antibody targeting Fzd4-mediated Wnt signaling designed using Surrozen's SWAP??

technology. It is currently being developed for the treatment of retinal vascular-associated diseases.